Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges

  • Oh, So Won (Department of Nuclear Medicine, Seoul National University Boramae Medical Center) ;
  • Cheon, Gi Jeong (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • Received : 2018.02.08
  • Accepted : 2018.06.02
  • Published : 2018.10.01
⟨ Previous Next ⟩

Abstract

The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)-targeting PET and their clinical applications in prostate cancer patients. There have been major strides in the design, synthesis of PSMA-targeting PET tracers over the past several years. PSMA-targeting PET tracers can be categorized, according to positron emitters and targeting strategies for the PSMA. The majority of PSMA PET studies has been focused on patients with biochemical recurrence, but additional values of PSMA PET have also been investigated for use in primary staging, treatment planning, response evaluation, and PSMA radioligand therapy. PSMA PET is expected to bring improvements in the management of patients, but the impact of improved diagnosis by PSMA on overall survival remains unanswered. Many challenges still await PSMA PET to expedite the use in the clinical practice. At this early stage, prospective multicenter trials are needed to validate the effectiveness and usefulness of PSMA PET.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea

References

  1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-548 https://doi.org/10.1001/jamaoncol.2016.5688
  2. Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC, Isaacs JT. Prostate cancer--biology of metastasis and its clinical implications. World J Urol 1996;14:182-189
  3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974 https://doi.org/10.1001/jama.280.11.969
  4. Serefoglu EC, Altinova S, Ugras NS, Akincioglu E, Asil E, Balbay MD. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J 2013;7:E293-E298 https://doi.org/10.5489/cuaj.1248
  5. Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 2013;189:2039-2046 https://doi.org/10.1016/j.juro.2013.02.072
  6. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85
  7. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261 https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
  8. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-539 https://doi.org/10.1002/jcb.10661
  9. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011;108:9578-9582 https://doi.org/10.1073/pnas.1106383108
  10. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-6362
  11. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558 https://doi.org/10.1002/ijc.2910620511
  12. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171(6 Pt 1):2122-2127 https://doi.org/10.1097/01.ju.0000123981.03084.06
  13. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-3603
  14. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with $^{11}C$-choline PET/CT. J Nucl Med 2006;47:1249-1254
  15. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-1649
  16. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-324 https://doi.org/10.1007/s00259-003-1377-9
  17. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus $^{68}Ga$-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185-1190 https://doi.org/10.2967/jnumed.115.160382
  18. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. $^{68}Ga$-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016;70:553-557 https://doi.org/10.1016/j.eururo.2015.12.051
  19. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by $^{68}Ga$-PSMA-positron emission tomography/computerized tomography. Prostate 2015;75:1934-1940 https://doi.org/10.1002/pros.23091
  20. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and $^{68}Ga$-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-2121 https://doi.org/10.1007/s00259-016-3435-0
  21. Ren J, Yuan L, Wen G, Yang J. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis. Acta Radiol 2016;57:487-493 https://doi.org/10.1177/0284185115581541
  22. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A phase I/II study for analytic validation of $^{89}Zr$-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res 2015;21:5277-5285 https://doi.org/10.1158/1078-0432.CCR-15-0552
  23. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197-209 https://doi.org/10.1007/s00259-014-2949-6
  24. Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008;51:7933-7943 https://doi.org/10.1021/jm801055h
  25. Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. $^{68}Ga$-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688-697 https://doi.org/10.1021/bc200279b
  26. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20 https://doi.org/10.1007/s00259-013-2525-5
  27. Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 2016;43:1611-1620 https://doi.org/10.1007/s00259-016-3419-0
  28. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. $^{68}Ga$-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017;44:1014-1024 https://doi.org/10.1007/s00259-017-3670-z
  29. Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 2016;18:428-436 https://doi.org/10.1007/s11307-016-0945-x
  30. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [$^{68}Ga$]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-495 https://doi.org/10.1007/s00259-012-2298-2
  31. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of $^{18}F$-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53:1883-1891 https://doi.org/10.2967/jnumed.112.104661
  32. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[$^{18}F$]fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [$^{18}F$]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 2011;17:7645-7653 https://doi.org/10.1158/1078-0432.CCR-11-1357
  33. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [($^18$)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015;17:565-574 https://doi.org/10.1007/s11307-015-0850-8
  34. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44:678-688 https://doi.org/10.1007/s00259-016-3573-4
  35. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2015;67:299-309 https://doi.org/10.1016/j.eururo.2014.02.011
  36. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-137 https://doi.org/10.1016/j.eururo.2013.09.046
  37. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-385 https://doi.org/10.1148/radiol.2312030011
  38. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L, et al. Endorectal and dynamic contrastenhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190:1187-1192 https://doi.org/10.2214/AJR.07.3032
  39. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19:761-769 https://doi.org/10.1007/s00330-008-1174-8
  40. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012;81:700-708 https://doi.org/10.1016/j.ejrad.2011.01.095
  41. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid $^{68}Ga$-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-674 https://doi.org/10.2967/jnumed.115.154153
  42. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive $^{68}Ga$-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016;70:926-937 https://doi.org/10.1016/j.eururo.2016.06.021
  43. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015;42:1284-1294 https://doi.org/10.1007/s00259-015-3078-6
  44. Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016;43:397-403 https://doi.org/10.1007/s00259-015-3240-1
  45. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-629 https://doi.org/10.1016/j.eururo.2016.08.003
  46. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014;43:1503-1513 https://doi.org/10.1007/s00256-014-1903-9
  47. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-395 https://doi.org/10.1016/j.crad.2007.05.022
  48. Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9:850-856 https://doi.org/10.1016/S1470-2045(08)70203-1
  49. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.; European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-479 https://doi.org/10.1016/j.eururo.2013.11.002
  50. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:1251-1265 https://doi.org/10.1016/j.eururo.2009.03.012
  51. van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of $^{68}Gallium$-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017;119:209-215 https://doi.org/10.1111/bju.13540
  52. Kolthammer JA, Su KH, Grover A, Narayanan M, Jordan DW, Muzic RF. Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-rate conditions. Phys Med Biol 2014;59:3843-3859 https://doi.org/10.1088/0031-9155/59/14/3843
  53. Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69:393-396 https://doi.org/10.1016/j.eururo.2015.06.010
  54. Laidler P, Dulin' ska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005;435:1-14 https://doi.org/10.1016/j.abb.2004.12.003
  55. Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:1400-1406 https://doi.org/10.1007/s00259-016-3346-0
  56. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous $^{68}Ga$-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 2016;70:829-836 https://doi.org/10.1016/j.eururo.2015.12.053
  57. Zumsteg ZS, Daskivich TJ, Sandler HM. Salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy. J Clin Oncol 2016;34:3829-3833 https://doi.org/10.1200/JCO.2016.69.2509
  58. Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 2012;84:112-118 https://doi.org/10.1016/j.ijrobp.2011.10.077
  59. Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 2013;86:822-828 https://doi.org/10.1016/j.ijrobp.2013.05.029
  60. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. $^{68}Ga$-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA < 1.0 ng/ml: impact on salvage radiotherapy planning. J Nucl Med 2018;59:230-237 https://doi.org/10.2967/jnumed.117.201749
  61. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-150S https://doi.org/10.2967/jnumed.108.057307
  62. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med 2015;56:1697-1705 https://doi.org/10.2967/jnumed.115.161299
  63. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating $^{177}Lu$-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017;58:85-90 https://doi.org/10.2967/jnumed.116.183194
  64. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of $^{177}Lu$-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med 2016;57:1334-1338 https://doi.org/10.2967/jnumed.116.173757
  65. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. $^{177}Lu$-labeled prostate-specific membrane antigen radioligand therapy of metastatic castrationresistant prostate cancer: safety and efficacy. J Nucl Med 2016;57:1006-1013 https://doi.org/10.2967/jnumed.115.168443
  66. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with $^{177}Lu$-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016;7:12477-12488
  67. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of $^{68}Ga$-labelled PSMA-11 and $^{11}C$-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 2017;44:92-101 https://doi.org/10.1007/s00259-016-3490-6
  68. Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [$^{68}Ga$]PSMA I&T and comparison with published data of [$^{68}Ga$]PSMA HBED-CC. Eur J Nucl Med Mol Imaging 2017;44:670-677 https://doi.org/10.1007/s00259-016-3572-5
  69. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [ (68) Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 2015;17:575-584 https://doi.org/10.1007/s11307-015-0866-0
  70. Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of $^{18}F$- and $^{68}Ga$-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med 2017;58:947-952 https://doi.org/10.2967/jnumed.116.185538
  71. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62:902-909 https://doi.org/10.1016/j.eururo.2012.01.047
  72. Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal USMR fusion guidance versus systematic biopsy--prospective multicenter study. Radiology 2013;268:461-469 https://doi.org/10.1148/radiol.13121501
  73. Yakar D, Debats OA, Bomers JG, Schouten MG, Vos PC, van Lin E, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging 2012;35:20-31 https://doi.org/10.1002/jmri.22790
  74. Souvatzoglou M, Eiber M, Takei T, Furst S, Maurer T, Gaertner F, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:1486-1499 https://doi.org/10.1007/s00259-013-2467-y
  75. de Perrot T, Rager O, Scheffler M, Lord M, Pusztaszeri M, Iselin C, et al. Potential of hybrid $^{18}F$-fluorocholine PET/MRI for prostate cancer imaging. Eur J Nucl Med Mol Imaging 2014;41:1744-1755 https://doi.org/10.1007/s00259-014-2786-7
  76. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a $^{68}Ga$-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014;41:887-897 https://doi.org/10.1007/s00259-013-2660-z
  77. Freitag MT, Kesch C, Cardinale J, Flechsig P, Floca R, Eiber M, et al. Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 2018;45:340-347 https://doi.org/10.1007/s00259-017-3854-6
  78. Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016;69:393-396 https://doi.org/10.1016/j.eururo.2015.06.010
  79. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016;195:1436-1443 https://doi.org/10.1016/j.juro.2015.12.025
  80. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in $^{68}Ga$- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging 2017;44:765-775 https://doi.org/10.1007/s00259-016-3578-z
  81. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017;44:2117-2136 https://doi.org/10.1007/s00259-017-3780-7

Cited by

  1. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  2. Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions vol.14, pp.1, 2018, https://doi.org/10.1371/journal.pone.0210297
  3. Multimodality Imaging of Prostate Cancer vol.60, pp.10, 2019, https://doi.org/10.2967/jnumed.119.228320
  4. Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer vol.322, pp.2, 2018, https://doi.org/10.1007/s10967-019-06800-6
  5. Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer vol.11, pp.47, 2018, https://doi.org/10.1021/acsami.9b15195
  6. Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma vol.13, pp.7, 2018, https://doi.org/10.3390/cancers13071508
  7. Developing μSpherePlatform Using a Commercial Hairbrush: An Agarose 3D Culture Platform for Deep-Tissue Imaging of Prostate Cancer vol.4, pp.5, 2021, https://doi.org/10.1021/acsabm.1c00086
  8. Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review vol.13, pp.6, 2018, https://doi.org/10.3390/sym13060974